Mizuho Financial (MFG) Company Overview

I have upgraded my rating for Mizuho Financial Group, Inc. to a Buy because of its strategic investment in Rakuten Card and the restart of share repurchases. The 15% ownership in Rakuten Card is likely to improve the company's business mix and increase its Return On Equity. Additionally, Mizuho's first share buyback in 16 years and a 24% increase in dividends indicate strong returns for shareholders, which boosts investor confidence.

Mizuho Financial Group, Inc. (NYSE:MFG) will hold its Q2 2024 earnings conference call on November 16, 2024, at 1:30 AM ET. The call will feature company representatives, including Orita Natsuki, the Chief Investor Relationship Officer, and Masahiro Kihara, the President and Group CEO. Takahiro Yano from J.P. Morgan Securities Japan Co., Ltd. will also participate in the call.

The global attention has mainly been on the choices of the United States Federal Reserve (the Fed), especially about interest rates and the economy's condition. Since inflation has been controlled well, the Fed has chosen to lower interest rates at the fastest rate in 16 years.

With US inflation appearing to decrease, many on Wall Street are optimistic about a "soft landing" for the economy. However, Mizuho, Japan's third-largest bank, cautions that if this expectation is incorrect, it may result in short-term fluctuations in the market.

Mizuho (MFG) could see an increase in its stock price due to rising confidence in its earnings potential, as indicated by its upgrade to a Zacks Rank #2 (Buy).

On August 28, 2024, Mizuho Americas announced that Thierry Perrein has been appointed as Managing Director and Credit Strategist. He will mainly focus on REITs and Non-bank Financials, enhancing Mizuho's services in these areas. Thierry will report to Brian Connors, who is the Managing Director and Head of Investment Grade Trading in Mizuho Americas' Fixed Income Division.

WUXI and SUZHOU, China, Aug. 1, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a top global Contract Research, Development and Manufacturing Organization (CRDMO), has announced that four of its manufacturing sites and the Suzhou Biosafety Testing Center in China have received Good Manufacturing Practice (GMP) certificates from the European Medicines Agency (EMA). This achievement highlights the company's dedication to maintaining high international quality standards across its operations. After thorough inspections of its facilities in Wuxi, the EMA granted GMP certificates for the production and services related to eight biologics, confirming WuXi Bio's ability to serve clients worldwide.

Investors interested in stocks from the Banks - Foreign sector have probably already heard of Mizuho (MFG) and ICICI Bank Limited (IBN). But which of these two stocks is more attractive to value investors?

NEW YORK, June 26, 2024 (GLOBE NEWSWIRE) -- Mizuho Financial Group, Inc. hereby announces that it filed an annual report on Form 20-F with the U.S. Securities and Exchange Commission on June 26, 2024.